Lucie Ecker - Concepedia

Author

Lucie Ecker

Instituto de Investigación Nutricional ORCID

Also Known As

Ecker, Lucie, Ecker-Ledesma, Lucie, L Ecker, Lucie Ecker, Lucie Ecker Ledesma, Lucie Ecker-Ledesma

Publications

417

Citations

H-Index

Concepts

All Affiliations

Instituto de Investigación Nutricional Universidad Peruana Cayetano Heredia The University of Texas Health Science Center at Houston CureVac (Germany)Universidad de Especialidades

About

Lucie Ecker is an author at Instituto de Investigación Nutricional.

Lucie Ecker

Publications

370

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri, The Lancet Infectious Diseases	2021	170
Factors Affecting Caregivers’ Use of Antibiotics Available Without a Prescription in Peru Lucie Ecker, Theresa J. Ochoa, Martha Vargas, PEDIATRICS	2013	38
Quantitative Real-time Polymerase Chain Reaction for Enteropathogenic Escherichia coli: A Tool for Investigation of Asymptomatic Versus Symptomatic Infections Francesca Barletta, Theresa J. Ochoa, Erik H. Mercado, Greater South Information System	2011	35
Safety and Immunogenicity of an Investigational Fully Liquid Hexavalent DTaP-IPV-Hep B-PRP-T Vaccine at Two, Four and Six Months of Age Compared With Licensed Vaccines in Latin America M. Macías, Claudio F. Lanata, Betzana Zambrano, The Pediatric Infectious Disease Journal	2012	35
Immunogenicity and Safety of a Fully Liquid DTaP-IPV-Hep B-PRP-T Vaccine at 2-4-6 Months of Age in Peru Claudio F. Lanata, Betzana Zambrano, Lucie Ecker Journal of Vaccines & Vaccination	2012	26
Physicians' responsibility for antibiotic use in infants from periurban Lima, Peru. Lucie Ecker, Liset Olarte, Gustavo Vilchez, PubMed	2011	21
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study Xavier Sáez‐Llorens, Claudio F. Lanata, Elaine Aranguren, Vaccine X	2022	19
Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri, SSRN Electronic Journal	2021	14
SARS‐CoV‐2 infections in households in a peri‐urban community of Lima, Peru: A prospective cohort study Claudio F. Lanata, Ana M. Gil, Lucie Ecker, Influenza and Other Respiratory Viruses	2021	12

Page 1